LivaNova stock holds near 80 USD as investors digest latest earnings and ownership shift

Published on 09/01/2026 at 21:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

LivaNova stock is trading just under 80 USD as of September 1, 2026, while investors weigh the latest quarterly earnings beat and a sizable recent share sale by an institutional holder.

LIVN, US5356991077, Illustration mit AI erstellt.

LivaNova PLC stock (ISIN US5356991077) is trading at about 79.81 USD as of September 1, 2026, leaving the medical technology group in a stable range after its latest earnings beat and a notable adjustment in institutional ownership.

Recent earnings beat underpins valuation

According to an overview reported by MarketBeat on September 1, 2026, LivaNova shares opened at 79.81 USD, with the stock supported by a 50 day moving average price of 80.64 USD and a 200 day moving average price of 72.49 USD, highlighting the medium term uptrend in the share price.

The same MarketBeat snapshot cites LivaNova's most recent quarterly earnings data, where the company reported earnings per share of 1.26 USD for the quarter ended August 6, 2026, compared with a consensus estimate of 1.09 USD. This represents a positive surprise of 0.17 USD per share and illustrates that the company outpaced expectations on profitability in that period.

In this latest quarter, LivaNova generated revenue of 390.59 million USD, as reported in the MarketBeat summary, compared with analyst expectations of 380.50 million USD. Revenue therefore exceeded the consensus by around 10.09 million USD, and the reported 10.8 percent year over year increase signals that the company is managing to grow its top line at a solid pace in its core markets.

Profitability metrics and analyst expectations

Beyond headline earnings and revenue, investors are paying attention to profitability ratios. The MarketBeat figures show that LivaNova delivered a return on equity of 16.35 percent in the latest reported quarter, underscoring efficient use of shareholder capital in the medical devices segment.

Net margin for the same quarter was reported at 12.82 percent in the MarketBeat data, indicating that LivaNova converts a meaningful portion of its revenue into net income despite regulatory and pricing pressures typical for the healthcare sector.

Sell side analysts, as summarized in the MarketBeat article, expect LivaNova PLC to post full year earnings per share of 3.77 USD for the current year. For investors, this forecast offers a reference point when comparing the current share price near 79.81 USD with the company's earnings power and assessing whether the valuation is consistent with sector peers.

Go deeper

More on LivaNova PLC fundamentals and news

Additional company news, filings and analyst commentary on LivaNova PLC can be found in the dedicated topic area on ad-hoc-news.de and via the companys investor relations page.

More articles on US5356991077 Investor Relations

Therapies and devices in the portfolio

LivaNova PLC focuses on medical technologies in areas such as cardiovascular surgery and neuromodulation, designing and manufacturing devices and therapies for conditions including heart failure and treatment resistant depression. These products and services form the revenue base that supported the 390.59 million USD in quarterly sales reported in the latest figures.

Stock price context and investor perspective

As of September 1, 2026, market data compiled by financial portals indicate that LivaNova PLC shares trade on the NASDAQ at around 79.81 USD, with a market capitalization near 4.38 billion USD, placing the company firmly in the mid cap segment among US listed medical device providers.